Product image of Norditropin Flexpro (Somatropin) supplied by GNH India

Norditropin Flexpro

Active Ingredient:
Somatropin
Origin:
EU

Norditropin Flexpro (Somatropin)

Somatropin, the active ingredient in Norditropin Flexpro, is a human growth hormone presented as a sterile solution for subcutaneous use. It is prescribed to treat growth hormone deficiency and related growth disorders in children, adolescents, and adults, and to support normal growth and metabolic functions in specific genetic or renal conditions.

GNH India supplies Norditropin Flexpro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU regulatory standards and is manufactured under GMP conditions, ensuring consistent potency and safety for patients.

Manufacturer / TM Owner

Novo Nordisk A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Norditropin Flexpro, a recombinant human growth hormone, is used in several endocrine and genetic conditions that affect growth.

  • Growth hormone deficiency in children and adolescents: promotes linear growth and improves height velocity.
  • Turner syndrome: enhances growth potential and increases final adult stature.
  • Prader‑Willi syndrome: supports growth and improves body composition.
  • Chronic renal insufficiency: helps counteract growth retardation associated with renal disease.
  • Adult growth hormone deficiency: restores metabolic balance and improves quality of life.

How It Works

  • Somatropin is a recombinant form of human growth hormone that binds to growth‑hormone receptors on target cells, activating the JAK2‑STAT5 signaling cascade. This stimulation increases hepatic production of insulin‑like growth factor‑1 (IGF‑1) and promotes protein synthesis, lipolysis, and bone growth, thereby facilitating linear growth in children and metabolic effects in adults.

Side Effects

Somatropin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain or erythema
  • Headache
  • Transient edema, especially in the extremities
  • Joint stiffness or arthralgia

Serious or Rare Side Effects

  • Intracranial hypertension
  • Development of anti‑GH antibodies leading to reduced efficacy
  • Hyperglycemia or new‑onset diabetes mellitus

Precautions & Warnings

When prescribing Somatropin, clinicians should consider several safety precautions to minimize risks.

  • Assess for active malignancy: avoid use in patients with known cancer due to potential growth stimulation.
  • Monitor glucose metabolism: check fasting glucose and HbA1c regularly in at‑risk individuals.
  • Evaluate intracranial pressure: watch for signs of headache, visual changes, or nausea.
  • Screen for thyroid function: hypothyroidism can worsen during therapy and should be corrected.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Somatropin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Glucocorticoids: high‑dose steroids may blunt the growth‑promoting effects of somatropin.
  • Antidiabetic agents: somatropin can exacerbate hyperglycemia, requiring dose adjustment of insulin or oral hypoglycemics.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone replacement: adequate levothyroxine is needed to achieve full growth response.
  • Estrogen therapy: high estrogen levels can reduce somatropin effectiveness in adolescents.
  • Oral contraceptives: may slightly increase IGF‑1 levels, necessitating monitoring.

Frequently Asked Questions

Norditropin Flexpro is a recombinant human growth hormone indicated for the treatment of growth hormone deficiency in children, adolescents and adults, as well as for specific conditions such as Turner syndrome, Prader‑Willi syndrome, chronic renal insufficiency, and short stature related to genetic abnormalities.

Somatropin mimics the body’s natural growth hormone. After subcutaneous injection it binds to growth‑hormone receptors, triggering a signaling cascade that raises insulin‑like growth factor‑1 (IGF‑1) levels, stimulates protein synthesis, bone growth, and metabolic processes that support linear growth and body composition.

The dose of Norditropin Flexpro is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s age, weight, diagnosis, and response to therapy, following current clinical guidelines.

Safety of somatropin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and decisions are made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Norditropin Flexpro is a recombinant somatropin formulation similar to other brands such as Genotropin or Humatrope. Differences may lie in device design, stability profile, and packaging, but the active molecule and clinical efficacy are comparable when administered according to prescribing information.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. If a pre‑filled pen is used, keep it in the original packaging until administration and discard any solution that appears cloudy or discolored.

Norditropin Flexpro is given by subcutaneous injection, typically into the thigh, abdomen, or upper arm. The injection is performed using the supplied pen or syringe, following aseptic technique and rotating injection sites to reduce local reactions.

Serious risks include intracranial hypertension, development of neutralising antibodies that reduce effectiveness, and metabolic disturbances such as hyperglycaemia or new‑onset diabetes. Patients should be monitored regularly for neurological symptoms, glucose changes, and signs of reduced therapeutic response.

Norditropin Flexpro is contraindicated in individuals with active malignancy, known hypersensitivity to somatropin or any excipients, and in patients with uncontrolled diabetes or severe acute illness where growth‑hormone therapy could be harmful.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Somatropin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT